The findings, presented today at the American Society of Clinical Oncology's annual meeting, mark the first clinical benefit of a small molecule targeted agent and standard chemotherapy in combination for lung cancer.

近日在美国临床肿瘤学会年会ASCO上，研究者首次公布了小分子靶向治疗药物-凡德他尼结合标准化疗方案可以使非小细胞肺癌临床受益。

Roy Herbst, MD, Ph.D., professor and chief of the section of MD Anderson's Department of Thoracic/Head and Neck Medical Oncology, presented the findings on ASCO's press program.

MD.安德森癌症中心胸/头颈部肿瘤内科主任 罗伊.赫布斯特教授在今年美国临床肿瘤学协会ASCO新闻发布会上介绍了这项研究结果。

"This study shows that an oral tyrosine kinase inhibitor can be combined with chemotherapy safely and effectively to provide systematic benefit to patients with this life-threatening disease," said Herbst.

“这项研究表明:口服酪氨酸激酶抑制剂-凡德他尼配合标准化疗方案，可以安全和有效地使非小细胞肺癌患者提供临床受益。

 "This study will have immediate clinical implications. Still, we need to build on this research and turn our focus toward better identifying molecular markers involved, with the ultimate goal of personalizing our patient's care."

罗伊.赫布斯特教授强调指出“这项研究将会具有很重要的临床指导意义。我们仍然需要在此研究基础上，将我们的研究重点转移到如何通过检测肿瘤分子标记物寻找确定最佳的受益人群，最终实现个性化的病人管理。 ”